Transformational therapies for the treatment of cardiovascular diseases

Learn More

Addressing Unmet Cardiovascular Needs

Orchestra BioMed is a therapeutic device company focused on the development and commercialization of high impact, data-driven, transformational solutions for targeted high value unmet medical needs. Our main focus is on developing new therapies for cardiovascular diseases which are the leading cause of death worldwide, taking the lives of 17.7 million people each year or 31% of all global deaths according to the World Health Organization. Cardiovascular diseases are the leading cause of death in the U.S. as well, causing 774,165 deaths or over 28.5% of all deaths in 2015 according to the CDC. Despite medical advancements, there remains significant need for improvement in clinical outcomes associated with cardiovascular disease.

[   17.7M people die every year from cardiovascular diseases   ]

Product Pipeline Overview

Product pipeline targets large initial markets with significant growth opportunities in expansion future indications.

Learn More

Transformational Therapies for Artery Disease & Hypertension

Innovative therapies target clear unmet needs in high risk patients

News & Events

Orchestra BioMed™ Strengthens Operations, R&D and Pharmaceutical Development Expertise with Key Leadership Team Additions

October 10, 2018

  • Ron Dadino appointed Vice President, Pharmaceutical Development & Operations, Cardiovascular Interventions
  • Greg Kopia, Ph.D., CMPP appointed Director, Pre-Clinical Development, Cardiovascular Interventions
  • Ziv Belsky appointed Vice President, Research & Development, Cardiac Neuromodulation

Orchestra BioMed™ Adds Three Industry Leaders to Strategic Advisory Board

October 9, 2018

  • Eric A. Rose, M.D., biotech and medical device business leader as well as world-renowned cardiac surgeon and scientist who performed the landmark achievement of the first successful pediatric heart transplant
  • Jason Aryeh, life sciences industry expert, investment fund manager and Director of licensing juggernaut Ligand Pharmaceuticals
  • Gary J. Pruden, former Worldwide Chairman for Johnson & Johnson Medical Devices Group and Executive Vice President of Johnson & Johnson
  • Expanded Strategic Advisory Board offers exceptional industry, product development, commercialization and capital markets strategic insight and expertise

Read All News